Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
Status:
Withdrawn
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is a prospective study that will explore the mechanisms of efficacy of dimethyl fumarate
(DMF) treatment in multiple sclerosis (MS). Investigators will enroll relapsing MS patients
who are beginning therapy with DMF into a one-year longitudinal study in which blood and
spinal fluid analyses, imaging and clinical studies will be performed to identify and measure
changes associated with DMF therapy.